Kidney Transplantation Clinical Trial
Official title:
Live Donor Renal Donation for Allotransplantation
NCT number | NCT00001856 |
Other study ID # | 990107 |
Secondary ID | 99-DK-0107 |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 17, 1999 |
Est. completion date | May 30, 2014 |
Verified date | May 30, 2014 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
On a yearly basis there are approximately 12,000 kidney transplants in the United States.
Presently there are approximately 40,000 patients awaiting a transplant with only 5,000
available donors. Due to the obvious difference between organ supply and demand, live donors
have become a standard source of kidneys for transplantation.
Research has proven that kidneys from living donors are superior to cadaveric donors (kidneys
harvested from a deceased individual). Kidneys from living donors are not exposed to
extremely low temperature that could increase post-operative problems. They are less likely
to experience rejection and there is a decreased likelihood that a patient will have to
undergo post-operative dialysis.
The objective of this study is to promote the enrollment of healthy individuals to serve as
kidney donors for patients undergoing research kidney transplantation at the NIH. Potential
donors will be screened to make sure they are able to survive with a single kidney without
significant medical risk. Additional tests will be taken to establish compatibility with the
recipient. Compatible donors will be evaluated to determine which kidney is suitable for
transplantation. Both the donation and transplantation procedure will be conducted on the
same day. Appropriate post-operative care and follow-up will be provided at the Clinical
Center.
Status | Completed |
Enrollment | 260 |
Est. completion date | May 30, 2014 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: Willingness to donate without evidence of secondary gain, coercion, or conflict of interest. Age greater than or equal to 18 years ABO compatible with recipient Normal renal function with a 24hr creatinine clearance greater than 80ml/min/1.73m(2). Willingness and legal ability to give informed consent Recipient is enrolled in a NIH protocol for transplantation or has been established as a candidate for receipt of an altruistic or paired donation through the Washington Regional Organ Procurement Agency donor program. EXCLUSION CRITERIA: Hypertension Pregnancy History of stroke Active tuberculosis History of active malignancies except basal cell carcinoma of the skin. Major anticipated illness or organ failure incompatible with survival after nephrectomy Functionally significant coronary artery disease. Active kidney stones Proteinuria (greater than 250mg/24hr) |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Cecka JM, Terasaki PI. The UNOS Scientific Renal Transplant Registry. Clin Transpl. 1993:1-18. — View Citation
Cicciarelli J. Living donor kidney transplants. Clin Transpl. 1988:293-9. — View Citation
Matas AJ, Gillingham KJ, Sutherland DE. Half-life and risk factors for kidney transplant outcome--importance of death with function. Transplantation. 1993 Apr;55(4):757-61. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 |